Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.54 |
| ▸ | PIK3R5 | Q8WYR1 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | STAT6 | P42226 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16172467 | 0.90 | SMN1; SMN2 (0.81) | SMN1; SMN2ALDH1A1PDE10AHPGDHIF1A | |
| SCHEMBL30455285 | 0.87 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1ACHEKDM4ESTAT6 | |
| SCHEMBL4092118 | 0.87 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1ACHEKDM4ESTAT6 | |
| SCHEMBL3318391 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1ACHEKDM4ESTAT6 | |
| SCHEMBL7267813 | 0.82 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1PDE10AHPGDHIF1A | |
| SCHEMBL27339271 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1PDE10AHPGDHIF1A | |
| SCHEMBL3527723 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1PDE10AHPGDAPP | |
| SCHEMBL4120999 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1PDE10AHPGDHIF1A | |
| SCHEMBL9132869 | 0.78 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL7268618 | 0.78 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1PDE10AHPGDHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104311494-A | m-(4-morpholinyl-2-quinazolinyl) benzamide compounds and synthetic method and application thereof | UNIV XI AN JIAOTONG | 2015-01-28 | — | — | CN | claimed |
| CN-104311494-A | m-(4-morpholinyl-2-quinazolinyl) benzamide compounds and synthetic method and application thereof | UNIV XI AN JIAOTONG | 2015-01-28 | — | — | CN | disclosed |
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2001867-B1 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-2001867-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110340-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | SMN1; SMN2 3802/4885ALDH1A1 2891/4885PDE10A 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.